KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Eli Lilly (LLY) Gross Margin (2016 - 2026)

Eli Lilly filings provide 18 years of Gross Margin readings, the most recent being 81.93% for Q1 2026.

  • On a quarterly basis, Gross Margin fell 59.0% to 81.93% in Q1 2026 year-over-year; TTM through Mar 2026 was 82.83%, a 113.0% increase, with the full-year FY2025 number at 83.04%, up 173.0% from a year prior.
  • Gross Margin hit 81.93% in Q1 2026 for Eli Lilly, down from 82.52% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 84.27% in Q2 2025 to a low of 73.47% in Q1 2022.
  • Median Gross Margin over the past 5 years was 80.89% (2023), compared with a mean of 80.16%.
  • The widest YoY moves for Gross Margin: up 693bps in 2022, down -162bps in 2022.
  • Eli Lilly's Gross Margin stood at 78.8% in 2022, then grew by 3bps to 80.89% in 2023, then rose by 2bps to 82.24% in 2024, then rose by 0bps to 82.52% in 2025, then dropped by -1bps to 81.93% in 2026.
  • The last three reported values for Gross Margin were 81.93% (Q1 2026), 82.52% (Q4 2025), and 82.91% (Q3 2025) per Business Quant data.